Early Is

Early detection of ovarian cancer is finally within reach

essential Evident has the potential to improve the course of diagnosis, treatment, and outcomes in this devastating disease.
Explore New Insights Contact Us

Early detection of ovarian cancer is finally within reach

Evident has the potential to improve the course of diagnosis, treatment, and outcomes in this devastating disease.
Explore New Insights Contact Us
Woman walking on the beach

Proactive Management

Early Detection,
Finally Possible

Ovarian cancer has been nearly impossible to detect early, often being diagnosed only at late stages when long-term survival is lowest. Until now, women had no reliable screening option to proactively manage their ovarian cancer risk.

Evident fills this critical gap. For the first time, patients and their providers have tools designed to identify ovarian cancer at its most treatable stages, often before noticeable symptoms appear.

Early detection can boost five-year survival from ~17% in advanced disease to ~90% in early stage disease1

Pacific Islander woman and adult daughter spending time together

Test Overview

Testing for Early, Actionable Answers

Evident is a simple blood test that provides accurate screening results with 98% specificity and almost 90% sensitivity in detecting stage I and II ovarian cancer.2 It offers women a dependable option to integrate early ovarian cancer detection into their standard preventive care. The Evident Screening test detects hidden early-stage ovarian cancer in average-risk postmenopausal women.

Impact

Empowering Women & their Physicians

Evident provides clear answers at a time when every moment counts. Detecting ovarian cancer early enough to make a meaningful difference, Evident can offer women peace of mind and offers physicians greater certainty in their clinical decision-making. Evident is desined to empower both individuals and their healthcare teams to take action as early as possible.

Postmenopausal Women can now have confidence in an accurate, regular screening test for ovarian cancer.

Physicians can be part of a new era in women’s health with innovation that offers a new way forward.

Technology

Science-Led, Patient-First

Discover the EV in Evident. Learn about the breakthrough extracellular vesicle (EV) technology that is unique to Evident and unlocks the ability to identify ovarian cancer early. Evident is built on rigorous clinical evidence and designed with patients and physicians at the center.

Explore the science behind Evident

Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples

Read More

Improving specificity for ovarian cancer screening using a novel extracellular vesicle-based blood test – Performance in a training and verification cohort

Read More

Colocalization of cancer-associated biomarkers on single extracellular vesicles for early detection of cancer

Read More
Smiling physician listening to her patient

Launch Program

Early Access Program Launching in Boston

Healthcare providers in the Boston area can join the regional launch of Evident in 2026. Be among the first to offer this revolutionary test and see how Evident is empowering patients and positioning physicians at the forefront of innovation in women’s health.

Parents and young child smiling

Our Vision

Making Early Detection the Standard

Evident was developed by Mercy Bio because early detection enables earlier intervention, more treatment options, and the chance for patients and their families to move forward with greater confidence. 

Our work began with ovarian cancer but now extends to redefining how early detection can shift the trajectory of care across multiple cancer types.

Mercy Bio envisions a future where aggressive cancers can be detected at their earliest, most treatable stages.

Want More

Information?

Contact us to learn more about Evident and early detection of ovarian cancer.

Smiling woman in a red shirt

The Evident test was developed, and the performance characteristics determined, by Mercy BioAnalytics Laboratories following Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority. The test is performed at Mercy BioAnalytics Laboratories. Mercy BioAnalytics Laboratories is certified under CLIA regulations and qualified to perform high-complexity clinical laboratory testing. ISO 13485 certified. @2026 Mercy BioAnalytics, Inc. All Rights Reserved.

References: 

  1. SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; July 2, 2025. Accessed November 19, 2025. Available at: https://seer.cancer.gov/statistics-network/explorer/. 
  2. Manning B, Banerjee S, Hawkins T, et al. Extracellular vesicle and particle-based blood test for ovarian cancer of average risk population: a promising nested case-control study using preclinical samples. Gynecol Oncol. 2025;203:26-34. doi:10.1016/j.ygyno.2025.10.003